US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AgomAb Therapeutics

13.17

0.0000

Post-market: 13.170.00000.00%19:30 EDT

Volume:105.44K

Turnover:1.38M

Market Cap:648.60M

PE:-2.92

High:14.13

Open:13.15

Low:12.75

Close:13.17

52wk High:17.82

52wk Low:8.75

Shares:49.25M

Float Shares:13.84M

Volume Ratio:0.58

T/O Rate:0.76%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.5143

EPS(LYR):-168.1598

ROE:-39.22%

ROA:-20.58%

PB:6.04

PE(LYR):-0.08

Loading ...

Overview Company News Filings

Agomab Therapeutics NV files Form 3 initial beneficial ownership statement for Chief Medical Officer Philippe Constantin Wiesel

Agomab Therapeutics NV Director Felice Isabel Verduyn-van Weegen Files Initial Beneficial Ownership Statement

Agomab Therapeutics NV Director Angelika Martha Jahreis Files Initial Beneficial Ownership Statement

Agomab Therapeutics Nv : Van Lanschot Kempen Initiates Coverage With Buy Rating; Price Target $33

THOMSON REUTERS

Morgan Stanley Sticks to Their Buy Rating for AgomAb Therapeutics NV ADR (AGMB)

AgomAb Therapeutics NV ADR (AGMB) Gets a Buy from Leerink Partners

JPMorgan Initiates AgomAb Therapeutics at Overweight

MT Newswires Live

Morgan Stanley Initiates AgomAb Therapeutics at Overweight

MT Newswires Live

Leerink Initiates AgomAb Therapeutics at Outperform With $36 Price Target

MT Newswires Live

Agomab Therapeutics Nv : Leerink Partners Initiates Coverage With Outperform Rating; Target Price $36

THOMSON REUTERS

AgomAb Therapeutics Initiated at Overweight by Morgan Stanley

Agomab Therapeutics Nv : JP Morgan Initiates Coverage With Overweight Rating; Target Price $32

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/AGMB/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AGMB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","market":"US","secType":"STK","nameCN":"AgomAb Therapeutics","latestPrice":13.17,"timestamp":1788206400000,"preClose":13.17,"halted":0,"volume":105442,"hourTrading":{"tag":"盘后","latestPrice":13.17,"preClose":13.17,"latestTime":"19:30 EDT","volume":13,"amount":170.53,"timestamp":1788219002855,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0,"floatShares":13836000,"shares":49248000,"eps":-4.51426,"marketStatus":"Closed","change":0,"latestTime":"08-31 16:00:00 EDT","open":13.15,"high":14.13,"low":12.75,"amount":1377528.02944,"amplitude":0.104784,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.51426,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788249600000},"marketStatusCode":5,"adr":0,"listingDate":1770354000000,"exchange":"NASDAQ","adjPreClose":13.17,"preHourTrading":{"tag":"盘前","latestPrice":13.6,"preClose":13.17,"latestTime":"09:28 EDT","volume":96,"amount":1307.040096,"timestamp":1788182880007,"change":0.43,"changeRate":0.03265,"amplitude":0.002278},"postHourTrading":{"tag":"盘后","latestPrice":13.17,"preClose":13.17,"latestTime":"19:30 EDT","volume":13,"amount":170.53,"timestamp":1788219002855,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.584563},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","floatShares":13836000,"roa":"-20.58%","roe":"-39.22%","lyrEps":-168.159829,"volumeRatio":0.584563,"shares":49248000,"dividePrice":0,"high":14.13,"amplitude":0.104784,"preClose":13.17,"low":12.75,"week52Low":8.75,"pbRate":"6.04","week52High":17.82,"institutionHeld":0,"latestPrice":13.17,"eps":-4.51426,"divideRate":0,"volume":105442,"delay":0,"ttmEps":-4.51426,"open":13.15,"prevYearClose":16,"prevWeekClose":13.17,"prevMonthClose":12.87,"prevQuarterClose":12.98,"fiveDayClose":12.82,"twentyDayClose":13.52,"sixtyDayClose":11.89},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AGMB\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AGMB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AGMB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1787889600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AGMB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AGMB","date":"2026-08-28","current":-2.917422,"percent":0.539568,"low":-14.725744,"twenty":-12.380686,"median":-8.974146,"eighty":-7.796268,"high":-6.52172,"avg":-9.647879,"sd":2.254804,"marketCap":681591974},"quantilePoints":[{"date":"2026-02-06","current":-14.293959,"twenty":-14.293959,"median":-14.293959,"eighty":-14.293959,"marketCap":779788464},{"date":"2026-02-13","current":-13.901135,"twenty":-14.202947,"median":-13.85921,"eighty":-13.805127,"marketCap":763217959},{"date":"2026-02-20","current":-13.975141,"twenty":-14.020702,"median":-13.811207,"eighty":-13.436782,"marketCap":760781120},{"date":"2026-02-27","current":-14.297833,"twenty":-14.274685,"median":-13.837477,"eighty":-13.631029,"marketCap":780275831},{"date":"2026-03-06","current":-12.944797,"twenty":-14.315694,"median":-13.869306,"eighty":-13.479283,"marketCap":692549629},{"date":"2026-03-13","current":-12.71107,"twenty":-14.294734,"median":-13.805127,"eighty":-12.961754,"marketCap":677928595},{"date":"2026-03-20","current":-11.600011,"twenty":-14.274685,"median":-13.584093,"eighty":-12.695924,"marketCap":618957093},{"date":"2026-03-27","current":-10.84065,"twenty":-14.216331,"median":-13.160447,"eighty":-12.395453,"marketCap":578505566},{"date":"2026-04-02","current":-10.748527,"twenty":-14.066263,"median":-13.052487,"eighty":-11.414439,"marketCap":574119256},{"date":"2026-04-10","current":-9.193391,"twenty":-13.930737,"median":-12.827934,"eighty":-10.709469,"marketCap":497602513},{"date":"2026-04-17","current":-10.018749,"twenty":-13.86294,"median":-12.650405,"eighty":-9.901184,"marketCap":545851924},{"date":"2026-04-24","current":-9.622204,"twenty":-13.825362,"median":-12.457995,"eighty":-9.650988,"marketCap":521483535},{"date":"2026-05-01","current":-7.206485,"twenty":-13.809991,"median":-11.744798,"eighty":-9.486381,"marketCap":528794052},{"date":"2026-05-08","current":-7.639457,"twenty":-13.779732,"median":-11.111376,"eighty":-9.258769,"marketCap":562411874},{"date":"2026-05-15","current":-7.446972,"twenty":-13.702513,"median":-10.748527,"eighty":-8.300034,"marketCap":543697644},{"date":"2026-05-22","current":-7.434647,"twenty":-13.568448,"median":-10.364346,"eighty":-8.115636,"marketCap":538772846},{"date":"2026-05-29","current":-7.796965,"twenty":-13.4527,"median":-9.998785,"eighty":-7.794875,"marketCap":568321631},{"date":"2026-06-05","current":-8.053102,"twenty":-13.287949,"median":-9.784729,"eighty":-7.758816,"marketCap":585558422},{"date":"2026-06-12","current":-6.750851,"twenty":-13.127527,"median":-9.578953,"eighty":-7.536224,"marketCap":486569993},{"date":"2026-06-18","current":-6.929006,"twenty":-13.073014,"median":-9.501773,"eighty":-7.448225,"marketCap":497404547},{"date":"2026-06-26","current":-9.2886,"twenty":-13.035188,"median":-9.467948,"eighty":-7.458553,"marketCap":661400304},{"date":"2026-07-02","current":-8.166663,"twenty":-12.965993,"median":-9.467948,"eighty":-7.479819,"marketCap":584573463},{"date":"2026-07-10","current":-8.975013,"twenty":-12.944797,"median":-9.309036,"eighty":-7.532768,"marketCap":641701114},{"date":"2026-07-17","current":-8.479177,"twenty":-12.71107,"median":-9.193391,"eighty":-7.541408,"marketCap":606735052},{"date":"2026-07-24","current":-8.981683,"twenty":-12.707304,"median":-9.020605,"eighty":-7.554336,"marketCap":638746235},{"date":"2026-07-31","current":-8.723327,"twenty":-12.661785,"median":-8.978348,"eighty":-7.610114,"marketCap":628157921},{"date":"2026-08-07","current":-9.22434,"twenty":-12.557349,"median":-9.00807,"eighty":-7.636377,"marketCap":664847662},{"date":"2026-08-14","current":-8.931525,"twenty":-12.519309,"median":-9.035172,"eighty":-7.716456,"marketCap":686763011},{"date":"2026-08-21","current":-8.496488,"twenty":-12.423423,"median":-8.981683,"eighty":-7.781927,"marketCap":661400304},{"date":"2026-08-28","current":-8.778373,"twenty":-12.380686,"median":-8.974146,"eighty":-7.796268,"marketCap":681591974}],"updateTime":1788222925024},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AGMB\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620126441","title":"Agomab Therapeutics NV files Form 3 initial beneficial ownership statement for Chief Medical Officer Philippe Constantin Wiesel","url":"https://stock-news.laohu8.com/highlight/detail?id=2620126441","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620126441?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:02","pubTimestamp":1773864168,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics NV files Form 3 initial beneficial ownership statement for Chief Medical Officer Philippe Constantin Wiesel. Agomab Therapeutics reported an initial statement of beneficial ownership by Philippe Constantin Wiesel, its chief medical officer. The filing listed stock options covering 21,732 common shares with an exercise price of USD 1.13. It also listed stock options covering 155,433 common shares with an exercise price of USD 0.0005.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL7l047W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620726445","title":"Agomab Therapeutics NV Director Felice Isabel Verduyn-van Weegen Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620726445","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620726445?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:02","pubTimestamp":1773864154,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics reported an initial statement of beneficial ownership for director Felice Isabel Verduyn-van Weegen. The filing listed a stock option to buy 32,700 common shares. The option had an exercise price of USD 14.26. The option expiration date was Jan. 15, 2036.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLbglz9D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620264460","title":"Agomab Therapeutics NV Director Angelika Martha Jahreis Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620264460","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620264460?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:02","pubTimestamp":1773864149,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics reported an initial statement of beneficial ownership for director Angelika Jahreis. The filing listed stock options covering 94,438 common shares with an exercise price of USD 3.1. It also reported stock options for 31,505 common shares with an exercise price of USD 14.26.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL4WJWZN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620125813","title":"Agomab Therapeutics Nv : Van Lanschot Kempen Initiates Coverage With Buy Rating; Price Target $33","url":"https://stock-news.laohu8.com/highlight/detail?id=2620125813","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620125813?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:53","pubTimestamp":1773834818,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nFWN40613U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618992931","title":"Morgan Stanley Sticks to Their Buy Rating for AgomAb Therapeutics NV ADR (AGMB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618992931","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618992931?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:36","pubTimestamp":1773139003,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Buy rating on AgomAb Therapeutics NV ADR, with a price target of $28...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-their-buy-rating-for-agomab-therapeutics-nv-adr-agmb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-their-buy-rating-for-agomab-therapeutics-nv-adr-agmb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617391543","title":"AgomAb Therapeutics NV ADR (AGMB) Gets a Buy from Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2617391543","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617391543?lang=en_us&edition=fundamental","pubTime":"2026-03-05 18:05","pubTimestamp":1772705132,"startTime":"0","endTime":"0","summary":"In a report released on March 3, Thomas Smith from Leerink Partners initiated coverage with a Buy rating on AgomAb Therapeutics NV ADR and a price ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/agomab-therapeutics-nv-adr-agmb-gets-a-buy-from-leerink-partners-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/agomab-therapeutics-nv-adr-agmb-gets-a-buy-from-leerink-partners-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616474543","title":"JPMorgan Initiates AgomAb Therapeutics at Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2616474543","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616474543?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:34","pubTimestamp":1772541270,"startTime":"0","endTime":"0","summary":"JPMorgan Initiates AgomAb Therapeutics at Overweight","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616347923","title":"Morgan Stanley Initiates AgomAb Therapeutics at Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2616347923","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616347923?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:30","pubTimestamp":1772541037,"startTime":"0","endTime":"0","summary":"Morgan Stanley Initiates AgomAb Therapeutics at Overweight","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616347940","title":"Leerink Initiates AgomAb Therapeutics at Outperform With $36 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2616347940","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616347940?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:30","pubTimestamp":1772541030,"startTime":"0","endTime":"0","summary":"Leerink Initiates AgomAb Therapeutics at Outperform With $36 Price Target","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616441653","title":"Agomab Therapeutics Nv : Leerink Partners Initiates Coverage With Outperform Rating; Target Price $36","url":"https://stock-news.laohu8.com/highlight/detail?id=2616441653","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616441653?lang=en_us&edition=fundamental","pubTime":"2026-03-03 19:55","pubTimestamp":1772538949,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nFWN3ZR0YK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616346639","title":"AgomAb Therapeutics Initiated at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2616346639","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616346639?lang=en_us&edition=fundamental","pubTime":"2026-03-03 18:35","pubTimestamp":1772534100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AGMB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 03, 2026 05:35 ET (10:35 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616450390","title":"Agomab Therapeutics Nv : JP Morgan Initiates Coverage With Overweight Rating; Target Price $32","url":"https://stock-news.laohu8.com/highlight/detail?id=2616450390","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616450390?lang=en_us&edition=fundamental","pubTime":"2026-03-03 13:20","pubTimestamp":1772515224,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nFWN3ZR01Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":52,"code":"91000000","status":"200"}]}}